Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion

Molecular Biology Reports

Volumn 41, Issue 6, 2014, Pages 3853-3857

  Du, Xianjin ^a   Hu, Xiaorong ^a,b   Wei, Jie ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI POLYTECHNIC UNIVERSITY   (China)

Author keywords

Exendin 4; High mobility group box 1 protein; Myocardial ischemia; Preconditioning; Reperfusion

Indexed keywords

CREATINE KINASE; EXENDIN 4; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; EXENDIN (9-39); GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HBP1 PROTEIN, RAT; PEPTIDE; PEPTIDE FRAGMENT; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; ISCHEMIC POSTCONDITIONING; MALE; NONHUMAN; RAT; REPERFUSION INJURY; AGONISTS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

RATTUS;

ANIMALS; CREATINE KINASE; GENE EXPRESSION REGULATION; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; MYOCARDIAL REPERFUSION INJURY; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RECEPTORS, GLUCAGON; TUMOR NECROSIS FACTOR-ALPHA; VENOMS;

EID: 84902375846     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3252-0     Document Type: Article

References (26)

1. Frangoginis NG, Smith CW, Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53:31-47 (Pubitemid 34020764)
2. Gottlieb RA, Engler RL (1999) Apoptosis in myocardial ischemia-reperfusion. Ann N Y Acad Sci 874:412-426 (Pubitemid 29353249)
3. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195 (Pubitemid 34773774)
4. Bell CW, Jiang W, Reich CF et al (2006) The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291:C1318-C1325 (Pubitemid 44878603)
5. Andrassy M, Volz HC, Igwe JC et al (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117:3216-3226
6. Hu X, Jiang H, Bai Q et al (2009) Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 406:139-142
7. Andrassy M, Volz HC, Riedle N et al (2011) HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 270:245-253
8. Zhao D, Wang Y, Xu Y (2012) Decreased serum endogenous secretory receptor for advanced glycation endproducts and increased cleaved receptor for advanced glycation endproducts levels in patients with atrial fibrillation. Int J Cardiol 158:471-472
9. Hu X, Fu W, Jiang H (2012) HMGB1: a potential therapeutic target for myocardial ischemia and reperfusion injury. Int J Cardiol 155:489
10. Kieffer TJ, Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913 (Pubitemid 30647076)
11. Bose AK, Mocanu MM, Carr RD et al (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146-151 (Pubitemid 40105106)
12. Sokos GG, Nikolaidis LA, Mankad S et al (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694-699 (Pubitemid 44881367)
13. Sonne DP, Engstrom T, Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243-249
14. Okerson T, Chilton RJ (2012) The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 30:e146-e155
15. Cai Y, Hu X, Yi B et al (2012) Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression. Mol Biol Rep 39:10705-10711
16. Wu L, Olverling A, Huang Z et al (2012) GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats. Clin Sci 122:375-384
17. Zhang K, Wu Y, Zhao L et al (2013) Exendin-4 attenuates ischemia-induced ventricular arrhythmias in rats. Cardiol J 20:29-33
18. Hu X, Cui B, Zhou X et al (2012) Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep 39:227-231
19. Timmers L, Henriques JPS, de Kleijn DPV et al (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501-510
20. Hu X, Zhou X, He B et al (2010) Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 638:84-89
21. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565-570 (Pubitemid 30666257)
22. Inoue K, Kawahara KI, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I (2007) HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16:136-143 (Pubitemid 46729668)
23. Kawahara K, Biswas KK, Unoshima M et al (2008) C-reactive protein induces high mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 17:129-138 (Pubitemid 351615295)
24. Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240-253
25. Hu X, Xu C, Zhou X et al (2011) PI3K/Akt signaling pathway involved in cardioprotection of preconditioning with high mobility group box 1 protein during myocardial ischemia and reperfusion. Int J Cardiol 150:222-223
26. Erdogdu O, Eriksson L, Xu H et al (2013) Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol 50:229-241